The pharmacokinetics of enteral antituberculosis drugs in patients requiring intensive care

South African Medical Journal

Volumn 103, Issue 6, 2013, Pages 394-398

  Koegelenberg, C F N ^a   Nortje, A ^a   Lalla, U ^a   Enslin, A ^a   Irusen, E M ^a   Rosenkranz, B ^a   Seifart, H I ^a   Bolliger, C T ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; RIMSTAR 4 FDC; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; WATER;

ADULT; APACHE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTENSIVE CARE; MALE; MAXIMUM PLASMA CONCENTRATION; NASOGASTRIC TUBE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84878362808     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/SAMJ.6344     Document Type: Article

References (29)

1. Bock N, Reichman LB. Tuberculosis and HIV/AIDS: Epidemiological and clinical aspects (World Perspective). Semin Respir Crit Care Med 2004;25:337-345. [http://dx.doi.org/10.1055/s-2004-829505]
2. Levy H, Kallenbach JM, Feldman C, Thorburn JR, Abramowitz JA. Acute respiratory failure in active tuberculosis. Crit Care Med 1987;15:221-225. [http://dx.doi.org/10.1097/00003246-198703000-00008]
3. Bernard G, Artigas A, Carlet J, et al. The American-European consensus conference on ARDS: Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149:818-824. [http://dx.doi.org/10.1007/BF01704707]
4. Silva DR, Menegotto DM, Schulz LF, Gazzana MB, Dalcin PT. Mortality among patients with tuberculosis requiring intensive care: a retrospective cohort study. BMC Infect Dis 2010;10:54. [http:// dx.doi.org/10.1186/1471-2334-10-54]
5. Tarling MM, Toner CC, Withington PS, Whelpton R, Goldhill DR. A model of gastric emptying using paracetamol absorption in intensive care patients. Intensive Care Med 1997;23:256-260. [http://dx.doi. org/10.1007/s001340050325]
6. Russel JA. Management of sepsis. N Engl J Med 2006;355:1699-1713. [http://dx.doi.org/10.1056/ NEJMra043632]
7. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002;62:2169-2183. [http://dx.doi.org/10.2165/00003495-200262150-00001]
8. Pinheiro VG, Ramos LM, Monteiro HS, et al. Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis. Braz J Infect Dis 2006;10:374-379. [http://dx.doi. org/10.1590/S1413-86702006000600003]
9. World Health Organization. Global Tuberculosis Report 2011. Geneva: World Health Organization, 2011. http://www.who.int/tb/publications/global_report/en (accessed 17 September 2012).
10. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644-1655. [http://dx.doi.org/10.1378/chest.101.6.1644]
11. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-829. [http://dx.doi.org/10.1097/00003246-198510000-00009]
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41. [http://dx.doi.org/10.1159/000180580]
13. Pai MP, Paloucek FP. The origin of the 'ideal' body weight equations. Ann Pharmacother 2000;34:1066-1069. [http://dx.doi.org/10.1345/aph.19381]
14. Seifart HI, Donald PR, De Villiers JN, Parkin DP, van Jaarsveld PP. Isoniazid elimination kinetics with protein-energy malnutrition treated for tuberculous meningitis with a four component antimicrobial regimen. Ann Trop Paediatr 1995;15:249-254.
15. Seifart HI, Gent WL, Parkin DP, Van Jaarsveld PP, Donald PR. High-performance liquid chromatographic (HPLC) determination of isoniazid, acetylisoniazid and hydrazine in biological fluids. Journal of Chromatography B Analyt Technol Biomed Life Sci 1995;674:269-275.
16. Parkin DP, Vandenplas S, Botha FJ, et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 1997;155:1717-1722.
17. Parkin DP, Vandenplas M, Vandenplas S, et al. Distribution of acetylator genotypes in the coloured population of the Western Cape region of South Africa. S Afr J Sci 1998;94:404-406.
18. Hall RG, Leff RD, Gumbo T. Treatment of active pulmonary tuberculosis in adults: Current standards and recent advances. Pharmacotherapy 2009;29(12):1468-1481. [http://dx.doi.org/10.1592/ phco.29.12.1468]
19. Long MW, Snider DE Jr, Farer LS. US public health service cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979;119:879-894.
20. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. Determinants of rifampicin, isoniazid, pyrazinamide and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006;50:1170-1177.
21. Kimerling ME, Phillips P, Patterson P, et al. Low serum antimycobacterial drug levels in non-HIV- infected tuberculosis patients. Chest 1998;5:1178-1183. [http://dx.doi.org/10.1378/chest.113.5.1178]
22. Chideya S, Winston CA, Peloquin CA, et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis 2009;48:1685-1694. [http://dx.doi.org/10.1086/599040]
23. Barroso EC, Pinheiro VG, Façanha MC, et al. Serum concentrations of rifampin, isoniazid, and intestinal absorption, permeability in patients with multidrug resistant tuberculosis. Am J Med Hyg 2009;81:322-329.
24. Marcial MA, Carlson SL, Madara JL. Partitioning of paracellular conductances along the ileal cryptvillus axis: a hypothesis based structural analysis with detailed consideration to tight-junction structure-function relationships. J Memb Biol 1984;80:59-70.
25. Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampicin under fasting conditions, with food, and with antacids. Chest 1999;115:12-18.
26. Stroud M, Duncan H, Nightingale J. Guidelines for enteral feeding in adult hospital patients. Gut 2003;52(Suppl 7):vii1-vii12. [http://dx.doi.org/10.1136/gut.52.suppl_7.vii1]
27. Ruslami R, Nijland HM, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother 2007;51:2546-2551. [http://dx.doi.org/10.1016/S1473-3099(12)70264-5]
28. Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 2013;13(1)27-35. [http://dx.doi.org/10.1016/S1473-3099(12)70264-5]
29. McIlleron H, Rustomjee R, Vahedi M, et al. Reduced antituberculosis drug concentrations in HIV- infected patients who are men or have low weight: implications for international dosing guidelines. Antimicrob Agents Chemother 2012;56:3232-3238. [http://dx.doi.org/10.1128/AAC.05526-11]